Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MDM2
REST API REST API
Homo sapiens
MDM2 is differentially expressed in 352 experiments: 158 organism parts: bone marrow, liver, ... (156 more);, 226 disease states: normal, control, ... (224 more);, 101 cell types 465 cell lines 52 compound treatments and 83 other conditions.
Synonyms MGC5370, HDMX, HDM2
Orthologs MDM2 (Bos taurus)   MDM2 (Gallus gallus)   ENSCING00000001188 (Ciona intestinalis)   mdm2 (Danio rerio)   Mdm2 (Mus musculus)   Mdm2 (Rattus norvegicus)   mdm2 (Xenopus laevis)   MDM2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ligase activity, plasma membrane, response to antibiotic, negative regulation of transcription, DNA-dependent, protein binding, establishment of protein localization, regulation of protein catabolic process, cytoplasm, protein catabolic process, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, intracellular, protein complex, protein ubiquitination, positive regulation of cell proliferation, negative regulation of apoptosis, metal ion binding, insoluble fraction, protein complex assembly, protein ubiquitination involved in ubiquitin-dependent protein catabolic process, fibroblast growth factor receptor signaling pathway, positive regulation of mitotic cell cycle, synaptic transmission, nucleus, ubiquitin-protein ligase activity, positive regulation of cell cycle, nuclear body, nucleoplasm, cell cycle checkpoint, negative regulation of transcription from RNA polymerase II promoter, enzyme binding, nucleolus, zinc ion binding, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, negative regulation of cell cycle arrest, cellular response to hypoxia, protein destabilization, interspecies interaction between organisms, p53 binding, nerve growth factor receptor signaling pathway, negative regulation of DNA damage response, signal transduction by p53 class mediator, traversing start control point of mitotic cell cycle, protein localization to nucleus, endocytic vesicle membrane, phosphatidylinositol-mediated signaling
InterPro Term SWIB_MDM2_domain, Znf_RanBP2, Znf_RING, p53_neg-reg_MDM_2/4
UniProt Accession Q96DS5, Q9H4C5, Q9H4C3, A7UKX7, A7UKY0, Q546E6, A8WFP2, Q00987, Q8NDW1, F5GWH7, E7EMW5, F5GZB0, F5GZC3, Q96DS0, E7EPE2, E5RJQ0, A7UKX8, E5RHE2, E9PF57, F5H1M7, F5H4Q8, Q86WA3
Search EB-eye ENSG00000135679
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
HepG2
2
E-MTAB-37, E-GEOD-7307
MOLT4
2
E-MTAB-62, E-MTAB-37
459 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-21909, ... (50 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3920, E-GEOD-26672
mononuclear
2
E-GEOD-13987, E-GEOD-26672
testis - leydig cell
1
E-AFMX-5
CD34+
1
E-TABM-145
CD11c+ dendritic cell
1
E-MEXP-1600
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (71 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-20602
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
melanoma
2
E-MTAB-62, E-MTAB-37
pancreatic carcinoma
2
E-MEXP-1121, E-MTAB-37
220 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (32 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-5824, E-TABM-868, E-GEOD-20719, E-GEOD-412, E-TABM-782, ... (12 experiments)
lipopolysaccharide
1
2
E-TABM-868, E-MEXP-1958, E-GEOD-3720
FLAP
1
E-GEOD-3202
valproic acid
1
E-GEOD-1615
CXCL4
1
E-GEOD-20484
unknown
1
E-GEOD-7307
46 more value(s).


Age at diagnosis

studied in E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
29
2
1
E-GEOD-21653
32 years
1
1
E-GEOD-4922
33
1
1
E-GEOD-21653
90 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-1801, E-MEXP-1901

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-MTAB-69, E-GEOD-22148, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-GEOD-18005, E-TABM-868, E-TABM-601, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (18 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (42 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743, E-GEOD-5372

Irradiate
studied in E-GEOD-1977, E-TABM-321

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.391 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM